Biomarker analysis as a decision-making tool in drug discovery and development: Implications for peroxisome proliferator-activator receptors

International Journal of Pharmaceutical Medicine

Volumn 21, Issue 4, 2007, Pages 271-277

  Stoch, S Aubrey ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIARRHYTHMIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CERIVASTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FARGLITAZAR; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; ROSIGLITAZONE; SIMVASTATIN; TAMOXIFEN;

CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGISTRATION; REVIEW; STRATIFICATION; VALIDATION STUDY;

EID: 34547108585     PISSN: 13649027     EISSN: 14735679     Source Type: Journal    
DOI: 10.2165/00124363-200721040-00003     Document Type: Review

References (44)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
2. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66
3. Ackerman BL, Hale JE, Duffin KL. The role of mass spectrometry in biomarker discovery and measurement. Curr Drug Metab 2006; 7: 525-39
4. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005; 59: 491-4
5. Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med 2005; 7 (11): 705-8
6. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002; 18: 41-6
7. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Disc 2004; 3: 763-9
8. Guidance for Industry. Pharmacogenomic data submissions. Mar 2005 [online]. Available from URL: http://www.fda.gov/cber/gdlns/pharmdtasub.pdf [Accessed 2007 Jul 10]
9. FDA-NIH conference: biomarkers and surrogate endpoints: advancing clinical research and applications [abstracts]. Dis Markers 1998; 14 (4): 187-334
10. Lathia CD. Biomarkers and surrogate endpoints: how and when might they impact drug development? Dis Markers 2002; 18: 83-90
11. Srivastava S, Wagner JA. Surrogate endpoints in medicine. Dis Markers 2002; 18: 39-40
12. Mol MJTM, Erkelens DW, Gevers JA, et al. Effects of simvastatin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet 1986 Oct 25; 2 (8513): 936-9
13. Lipids Research Clinics Program. The relationship of reduction in incidence of coronary artery heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
14. Exht DS, Liebon B, Mitchell RW, et al. Mortality and morbidity of patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. N Eng J Med 1991; 324: 781-8
15. Biomarkers Definitions Working Group. Biomarkers surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89-95
16. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177: 40-7
17. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845-56
18. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006; 6: 565-71
19. FDA clears genetic test that advances personalized medicine test helps determine safety of drug therapy. 2005 Aug 22 [press release; online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html [Accessed 2007 Jul 10]
20. Lewin DA, Weiner MP. Molecular biomarkers in drug development. Drug Disc Today 2004; 9 (22): 976-83
21. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143 (3): 998-1007
22. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator- activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25 (2): 376-80
23. Nawrocki AR, Scherer PE. The adipocyte as a drug discovery target. Drug Disc Today 2005; 10 (18): 1219-30
24. Bloom S. Prominent investigator wins diabetes research award. J Clin Invest 2005; 115: 1678
25. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmaocol 2005; 5: 122-8
26. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003; 2: 207-13
27. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703
28. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9
29. Schapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998; 8: 335-8
30. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocytesecreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-85
31. Rajala MW, Scherer PE. Minireview: The adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 5: 122-8
32. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100
33. Wang Y, Xu A, Knight C, et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. J Biol Chem 2002; 277: 19521-9
34. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9
35. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98: 2005-10
36. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6
37. Berg AH, Combatsiaris TC, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-53
38. Wagner JA. Early clinical development of pharmaceuticals for type 2 diabetes mellitus: from preclinical models to human investigation. J Clin Endo Metab 2002, 6
39. Wagner JA, Larson PJ, Weiss S, et al. Individual and combined effects of peroxisome proliferator-activated receptor α and γ agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 2005; 45: 504-13
40. Pajvani UB, Hawkins M, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279 (13): 12152-62
41. Das K, Lin Y, Widen E, et al. Chromosomal localization, expression pattern and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun 2001; 280: 1120-9
42. Tontonoz P, Hu E, Spiegelman BM. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr Biol 1995; 5: 571-6
43. O'Connor-Semmes R, Mydlow P, Walker A, et al. G1262570, a PPARγ agonist, maintains metabolic improvements throughout 24 hour profiles in type 2 diabetic patients. Diabetes 2000; 49 Suppl. 1: A119
44. Fiedorek FT, Wilson GG, Frith L, et al. Monotherapy with G1262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, improves metabolic control in type 2 diabetes patients. Diabetes 2000; 49 (Suppl. 1): A38